|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
EP0154316B1
(en)
|
1984-03-06 |
1989-09-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified lymphokine and production thereof
|
|
US5981216A
(en)
|
1985-04-01 |
1999-11-09 |
Alusuisse Holdings A.G. |
Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
|
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
EP0351410A1
(en)
|
1987-03-18 |
1990-01-24 |
3i RESEARCH EXPLOITATION LIMITED |
Complement-binding peptide
|
|
WO1988007089A1
(en)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
|
GB8709290D0
(en)
|
1987-04-16 |
1987-05-20 |
Secretary Trade Ind Brit |
Precision motion slideways
|
|
GB8717430D0
(en)
|
1987-07-23 |
1987-08-26 |
Celltech Ltd |
Recombinant dna product
|
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
EP0401384B1
(en)
|
1988-12-22 |
1996-03-13 |
Kirin-Amgen, Inc. |
Chemically modified granulocyte colony stimulating factor
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
EP1690934A3
(en)
|
1990-01-12 |
2008-07-30 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
ATE300615T1
(de)
|
1990-08-29 |
2005-08-15 |
Genpharm Int |
Transgene mäuse fähig zur produktion heterologer antikörper
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
GB9022543D0
(en)
|
1990-10-17 |
1990-11-28 |
Wellcome Found |
Antibody production
|
|
EP1291360A1
(en)
|
1991-12-13 |
2003-03-12 |
Xoma Corporation |
Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
WO1993022332A2
(en)
|
1992-04-24 |
1993-11-11 |
Board Of Regents, The University Of Texas System |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
|
NZ255101A
(en)
|
1992-07-24 |
1997-08-22 |
Cell Genesys Inc |
A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
|
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
|
US6091001A
(en)
|
1995-03-29 |
2000-07-18 |
Abgenix, Inc. |
Production of antibodies using Cre-mediated site-specific recombination
|
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
CA2219361C
(en)
|
1995-04-27 |
2012-02-28 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
AUPN568095A0
(en)
|
1995-09-27 |
1995-10-26 |
Austin Research Institute, The |
Anti-Galalpha(1,3)Gal antibody binding peptides
|
|
JP4046354B2
(ja)
|
1996-03-18 |
2008-02-13 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
増大した半減期を有する免疫グロブリン様ドメイン
|
|
CA2275141A1
(en)
|
1996-10-29 |
1998-05-07 |
Thomas Spies |
Cell stress regulated human mhc class i gene
|
|
EP1500329B1
(en)
|
1996-12-03 |
2012-03-21 |
Amgen Fremont Inc. |
Human antibodies that specifically bind human TNF alpha
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
US5830698A
(en)
|
1997-03-14 |
1998-11-03 |
Idec Pharmaceuticals Corporation |
Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
|
|
WO1998052976A1
(en)
|
1997-05-21 |
1998-11-26 |
Biovation Limited |
Method for the production of non-immunogenic proteins
|
|
ES2292236T3
(es)
|
1998-04-02 |
2008-03-01 |
Genentech, Inc. |
Variantes de anticuerpos y sus fragmentos.
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
ES2434961T5
(es)
|
1998-04-20 |
2018-01-18 |
Roche Glycart Ag |
Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
HU230769B1
(hu)
|
1999-01-15 |
2018-03-28 |
Genentech Inc. |
Módosított effektor-funkciójú polipeptid-változatok
|
|
EP1176195B1
(en)
|
1999-04-09 |
2013-05-22 |
Kyowa Hakko Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
|
US20090175821A1
(en)
|
1999-05-17 |
2009-07-09 |
Bridon Dominique P |
Modified therapeutic peptides with extended half-lives in vivo
|
|
US6475220B1
(en)
|
1999-10-15 |
2002-11-05 |
Whiteside Biomechanics, Inc. |
Spinal cable system
|
|
HUP0204475A2
(en)
|
2000-02-11 |
2003-04-28 |
Merck Patent Gmbh |
Enhancing the circulating half-life of antibody-based fusion proteins
|
|
US6725230B2
(en)
|
2000-07-18 |
2004-04-20 |
Aegis Analytical Corporation |
System, method and computer program for assembling process data of multi-database origins using a hierarchical display
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
WO2002068615A2
(en)
|
2001-02-28 |
2002-09-06 |
Fred Hutchinson Cancer Research Center, Inc. |
Activation of lymphocyte populations expressing nkg2d using anti-nkg2d antibodies and ligand derivatives
|
|
US20040115198A1
(en)
|
2001-02-28 |
2004-06-17 |
Fred Hutchinson Cancer Research Center |
Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives
|
|
US6566208B2
(en)
|
2001-07-25 |
2003-05-20 |
Chartered Semiconductor Manufacturing Ltd. |
Method to form elevated source/drain using poly spacer
|
|
US7084257B2
(en)
*
|
2001-10-05 |
2006-08-01 |
Amgen Inc. |
Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
|
|
HUP0600342A3
(en)
|
2001-10-25 |
2011-03-28 |
Genentech Inc |
Glycoprotein compositions
|
|
US7745140B2
(en)
|
2002-01-03 |
2010-06-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
|
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
AU2003217912A1
(en)
|
2002-03-01 |
2003-09-16 |
Xencor |
Antibody optimization
|
|
AU2003225093A1
(en)
*
|
2002-04-22 |
2003-11-03 |
Fred Hutchinson Cancer Research Center |
Soluble mic polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions
|
|
US7524630B2
(en)
|
2002-04-22 |
2009-04-28 |
University Of Florida Research Foundation, Inc. |
Functionalized nanoparticles and methods of use
|
|
EP1534335B9
(en)
|
2002-08-14 |
2016-01-13 |
Macrogenics, Inc. |
Fcgammariib-specific antibodies and methods of use thereof
|
|
WO2004029207A2
(en)
|
2002-09-27 |
2004-04-08 |
Xencor Inc. |
Optimized fc variants and methods for their generation
|
|
DE60334141D1
(de)
|
2002-10-15 |
2010-10-21 |
Facet Biotech Corp |
VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE
|
|
JP2006524039A
(ja)
|
2003-01-09 |
2006-10-26 |
マクロジェニクス，インコーポレーテッド |
変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
|
|
US7666417B2
(en)
|
2003-04-22 |
2010-02-23 |
Fred Hutchinson Cancer Research Center |
Methods and compositions for treating autoimmune diseases or conditions
|
|
US20100069614A1
(en)
*
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
CN102558352A
(zh)
*
|
2003-06-27 |
2012-07-11 |
艾默根佛蒙特有限公司 |
针对表皮生长因子受体的缺失突变体的抗体及其使用
|
|
US7871610B2
(en)
*
|
2003-08-12 |
2011-01-18 |
Dyax Corp. |
Antibodies to Tie1 ectodomain
|
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
|
CA2552788C
(en)
|
2004-01-12 |
2013-09-24 |
Applied Molecular Evolution, Inc. |
Fc region variants
|
|
EP1737890A2
(en)
|
2004-03-24 |
2007-01-03 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
|
KR100912994B1
(ko)
*
|
2004-04-05 |
2009-08-21 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
Ｎｋｇ２ｄ의 조절
|
|
PL1776384T3
(pl)
|
2004-08-04 |
2013-10-31 |
Mentrik Biotech Llc |
WARIANTY REGIONÓW Fc
|
|
BRPI0518209A
(pt)
*
|
2004-10-19 |
2008-11-04 |
Amgen Inc |
agentes de ligação especìficos à angiopoietina-2
|
|
US7780963B2
(en)
|
2004-10-25 |
2010-08-24 |
Merck & Co., Inc. |
Anti-ADDL antibodies and uses thereof
|
|
US20080148432A1
(en)
*
|
2005-12-21 |
2008-06-19 |
Mark Scott Abad |
Transgenic plants with enhanced agronomic traits
|
|
BRPI0519596B1
(pt)
*
|
2004-12-21 |
2022-01-18 |
Astrazeneca Ab |
Agente de ligação alvejado, anticorpo monoclonal que se liga a angiopoietina-2, molécula de ácido nucleico, vetor, e, uso do agente de ligação alvejado
|
|
CN101355965A
(zh)
|
2005-06-08 |
2009-01-28 |
达纳－法伯癌症研究院 |
通过抑制程序性细胞死亡1（pd-1）途经治疗持续性感染和癌症的方法及组合物
|
|
BRPI0617167B8
(pt)
*
|
2005-09-21 |
2021-05-25 |
Nycomed Gmbh |
sulfonilpirróis como inibidores de hdac's, seu uso, composição farmacêutica e combinação
|
|
EP1949107A1
(en)
|
2005-11-03 |
2008-07-30 |
Fred Hutchinson Cancer Research Center |
Negative immunomodulation of immune responses by nkg2d-positive cd4-positive cells
|
|
US8248965B2
(en)
|
2005-11-03 |
2012-08-21 |
Motorola Solutions, Inc. |
Method and apparatus regarding use of a service convergence fabric
|
|
CA2633211A1
(en)
*
|
2005-12-15 |
2007-06-21 |
Astrazeneca Ab |
Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer
|
|
DE102006009847A1
(de)
|
2006-03-01 |
2007-09-06 |
Sweredjuk, Robert, Dr. |
Verfahren von Absorbieren von Schadstoffen und Gerüchen
|
|
WO2008021076A2
(en)
|
2006-08-07 |
2008-02-21 |
President And Fellows Of Harvard College |
Protein matrix vaccines and methods of making and administering such vaccines
|
|
US20110060120A1
(en)
|
2006-09-08 |
2011-03-10 |
Obeid Michel Sarkis |
Immunogenic treatment of cancer by peptides inducing the plasma membrane exposure of erp57
|
|
CA2665090A1
(en)
|
2006-09-22 |
2008-03-27 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating mica-related disorders
|
|
EP2862579B1
(en)
*
|
2006-10-04 |
2017-05-17 |
Dana-Farber Cancer Institute, Inc. |
Tumor immunity
|
|
EP1944611A1
(en)
*
|
2007-01-11 |
2008-07-16 |
Université de la Méditerranée |
Biomarker for the medicine and the biology of the reproduction
|
|
CA2685056C
(en)
|
2007-04-23 |
2015-08-25 |
Fred Hutchinson Cancer Research Center |
Negative immunomodulation of immune responses by erp5
|
|
MX2009012343A
(es)
*
|
2007-05-14 |
2010-02-10 |
Biogen Idec Inc |
Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
|
|
US9370558B2
(en)
|
2008-02-13 |
2016-06-21 |
President And Fellows Of Harvard College |
Controlled delivery of TLR agonists in structural polymeric devices
|
|
WO2011063336A2
(en)
|
2009-11-20 |
2011-05-26 |
President And Fellows Of Harvard College |
Secondary site of antigen stimulation for therapeutic vaccination
|
|
US10328133B2
(en)
|
2008-02-13 |
2019-06-25 |
President And Fellows Of Harvard College |
Continuous cell programming devices
|
|
JO2913B1
(en)
*
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
|
WO2010011242A2
(en)
*
|
2008-03-24 |
2010-01-28 |
Beth Israel Deaconess Medical Center |
Methods and compositions for the treatment and diagnoisis of systemic anthrax infection
|
|
US8182809B1
(en)
|
2008-09-08 |
2012-05-22 |
University Of Washington |
Methods for treating cancer by inhibiting MIC shedding
|
|
US8133979B2
(en)
|
2008-12-16 |
2012-03-13 |
Hoffmann-La Roche Inc. |
Antibodies against human angiopoietin 2
|
|
US8207497B2
(en)
|
2009-05-08 |
2012-06-26 |
Ionsense, Inc. |
Sampling of confined spaces
|
|
JO3182B1
(ar)
|
2009-07-29 |
2018-03-08 |
Regeneron Pharma |
مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
|
|
KR101688522B1
(ko)
|
2009-12-15 |
2016-12-21 |
삼성전자주식회사 |
안지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도
|
|
US8796420B2
(en)
|
2009-12-31 |
2014-08-05 |
Avidbiotics Corp. |
Non-natural MIC proteins
|
|
SI2501817T2
(sl)
*
|
2010-02-08 |
2021-09-30 |
Regeneron Pharmaceuticals, Inc. |
Miš z navadno lahko verigo
|
|
US8753640B2
(en)
|
2011-05-31 |
2014-06-17 |
University Of Washington Through Its Center For Commercialization |
MIC-binding antibodies and methods of use thereof
|
|
CN102911270A
(zh)
*
|
2011-08-05 |
2013-02-06 |
浙江大学 |
一种抑制移植器官慢性排斥反应的抗体的制备及纯化方法
|
|
ES2925654T3
(es)
*
|
2011-09-30 |
2022-10-19 |
Dana Farber Cancer Inst Inc |
Péptidos terapéuticos que comprenden anticuerpos que se unen a la secuencia A relacionada con el polipéptido del CMH de clase I (MICA)
|
|
EP2812027A1
(en)
*
|
2012-02-07 |
2014-12-17 |
Innate Pharma |
Mica binding agents
|
|
KR20150130462A
(ko)
|
2013-03-15 |
2015-11-23 |
다나-파버 캔서 인스티튜트 인크. |
치료 펩티드
|
|
BR112015024543A2
(pt)
|
2013-03-28 |
2017-07-18 |
Honda Motor Co Ltd |
sistema de notificação, dispositivo eletrônico, método de notificação e programa
|
|
US9572898B2
(en)
|
2013-09-09 |
2017-02-21 |
Seton Hall University |
Functionalized fluorine containing phthalocyanine molecules
|
|
EA201691078A1
(ru)
|
2013-12-06 |
2017-01-30 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Терапевтические пептиды
|
|
WO2015139020A2
(en)
|
2014-03-14 |
2015-09-17 |
Dana-Farber Cancer Institute, Inc. |
Vaccine compositions and methods for restoring nkg2d pathway function against cancers
|
|
CA2945822A1
(en)
|
2014-05-21 |
2015-11-26 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer with anti bip or anti mica antibodies
|